The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taiwan's Tzu Chi Foundation delivers medical aid to flood-hit Nepal
08/29/2026 09:12 PM - Culture
Taiwanese American groups urge inclusion in planned museum
08/29/2026 08:48 PM - Society
Taiwan Railway showcases color-coded direction at new Tainan Station
08/29/2026 07:36 PM - Business
Taiwan should review past U.S. export control listings: Think tank
08/29/2026 06:17 PM - Society
TFDA orders recall of heart drug tablets over impurities
08/29/2026 06:09 PM